There are six cases known to the authorities in Belgium of problems with blood clotting after vaccination with the AstraZeneca vaccine.
These cases were recently reported after concerns were raised in the various EU countries, although they occurred before the recent media attention, according to the FAMHP.
Unlike many other EU countries, including the Netherlands, Belgium has not temporarily halted the vaccination campaign with the British-Swedish pharmaceutical company’s injections due to concerns about blood clots.
The FAMHP writes that “every year many thousands of people in the EU develop blood clots for various reasons”. The rate of blood clots in vaccinees does not appear to be higher in general than in the general population, the agency said.
“To date, six cases of thromboembolic events and other blood clot-related conditions have been reported in Belgium after AstraZeneca vaccination”.
For the time being, the FAMHP maintains that the benefits of the AstraZeneca vaccine in preventing Covid-19, with the associated risk of hospitalization and death, outweigh the risks of side effects. The European Medicines Agency EMA is currently analyzing the matter.